Elicio Therapeutics, Inc. (ELTX)
2.41
-0.09
(-3.60%)
USD |
NASDAQ |
Sep 04, 16:00
2.425
+0.02
(+0.62%)
After-Hours: 20:00
Elicio Therapeutics Research and Development Expense (Quarterly) : 6.775M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.775M |
| March 31, 2026 | 6.711M |
| December 31, 2025 | 5.031M |
| September 30, 2025 | 4.99M |
| June 30, 2025 | 6.953M |
| March 31, 2025 | 7.725M |
| December 31, 2024 | 10.62M |
| September 30, 2024 | 7.134M |
| June 30, 2024 | 8.10M |
| March 31, 2024 | 7.477M |
| December 31, 2023 | 5.871M |
| September 30, 2023 | 7.264M |
| June 30, 2023 | 4.944M |
| March 31, 2023 | 5.374M |
| Date | Value |
|---|---|
| December 31, 2022 | 3.996M |
| September 30, 2022 | 4.493M |
| June 30, 2022 | 5.041M |
| March 31, 2022 | 11.64M |
| December 31, 2021 | 6.636M |
| September 30, 2021 | 13.26M |
| June 30, 2021 | 14.42M |
| March 31, 2021 | 14.29M |
| December 31, 2020 | 11.05M |
| September 30, 2020 | 6.074M |
| June 30, 2020 | 12.18M |
| March 31, 2020 | 9.569M |
| December 31, 2019 | 10.43M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Precigen, Inc. | 6.963M |
| Agenus, Inc. | 14.76M |
| Amgen, Inc. | 1.868B |
| Anika Therapeutics, Inc. | 7.341M |
| BioCryst Pharmaceuticals, Inc. | 51.46M |